Infant Growth Clinical Trial
— EARLY-TOLERAOfficial title:
Evaluation of the Effect of a New Infant Formula With Specific Ingredients on the Development of the Immune System and the Gastrointestinal Health of the Infant
The purpose of this study is to test whether the addition of certain bioactive ingredients to a new infant formula (HMOs, osteopontin and probiotics) can have a favorable impact on the development of the infant's immune system in the first months of life.
Status | Recruiting |
Enrollment | 231 |
Est. completion date | September 2022 |
Est. primary completion date | September 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A to 2 Months |
Eligibility | Inclusion Criteria: - Inclusion age from 0 to 2.5 months of age. - Gestational age >37 weeks and <41 weeks inclusive. - Appropriate birth weight appropriate for your gestational age (between 10-90 percentiles). - APGAR score normal birth to 1' and 5' of 7 - 10. - Umbilical pH = 7.10. - Availability to continue throughout the study period. - Written informed consent Additional Inclusion Criteria for groups 1 and 2: - Infants who, at the time of recruitment, have already passed the diet with a majority or exclusive formula for medical reasons, by decision of the parents or any other reason agreed with the pediatrician. Additional Inclusion Criteria for group 3 (breastfeed infants): - Infants who have been breastfed until the second month with exclusive or majority breastfeeding. - Infants who are expected to be exclusively or predominantly breastfed up to 6 months. Exclusion Criteria: - Simultaneous participation in other clinical trials. - Infants suffering from gastrointestinal disorders (allergy and/or intolerance to cow's milk protein or lactose). - Mother's pathology history and during gestation: neurological diseases, metabolic disorders, type 1 diabetes mellitus, chronic disease (hypothyroidism), maternal malnutrition, TORCH syndrome. - Treatment of the mother's anxiolytics or antidepressants. Other treatments with drugs potentially harmful to neurodevelopment. - Inability of the parents to follow up the study (medical decision). |
Country | Name | City | State |
---|---|---|---|
Spain | Cristina Campoy | Granada | Andalucia |
Lead Sponsor | Collaborator |
---|---|
Laboratorios Ordesa | Universidad de Granada |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Register of infections | Register of infant infections through patient diaries completed by parents | From baseline to 12 months | |
Primary | Register of fever episodes | Presence and duration of the fever and treatments, through diaries completed by parents | From baseline to 12 months. | |
Primary | Register of diarrhea episodes | Presence and duration of diarrhea, registered in patients dairies. | From baseline to 12 months. | |
Secondary | Immune response evaluation | registration of Immunoglobulin secreted in saliva | At 3, 6 and 12 months of age | |
Secondary | Demographic data | age of the parents, educational level of the parents, habits and lifestyles of the parents, residence and social environment of the infant. | From baseline to 12 months. | |
Secondary | Obstetric background | Relevant obstetric background | Baseline | |
Secondary | Study of the infant microbiota | Stool bacteria count | At 3, 6 and 12 months. | |
Secondary | Assessment of normal growth of the infant | Evolution of Weight (g), Size (cm) to calculate the Body Mass Index.weight and height will be combined to report BMI in kg/m^2 | From baseline to 12 months. | |
Secondary | Infant neurodevelopment | Analysis of eye movements. Eye tracking technologies is using to assess early cognitive development to evaluate attention domain | At 12 months | |
Secondary | Infant neurodevelopment 2 | ASQ-3 (Ages & Stages Questionnaires®) ASQ-3 is a set of questionnaires about children's development | At 2, 3, 4, 6, 9 and 12 months of age. | |
Secondary | Infant neurodevelopment 3 | General Movements test (GM´s) GM's is using for the neurological assessment during the first months of life and measures a series of gross movements of variable amplitude and speed involving all body parts | At 2, 3 and 4 months of life. | |
Secondary | Infant neurodevelopment 4 | Bayley´s Scales of Infant Development III (Spanish version BSID III) is using to evaluate psychomotor and mental development . | 6 and 12 months of age | |
Secondary | Infant neurodevelopment 5 | MacArthur Communicative Development Inventory (CDI) . This test assesses the normal process of early language acquisition by various manifestations | 12 months of age |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06091917 -
Modulating Early-life Nutrition for Childhood Obesity Prevention
|
N/A | |
Completed |
NCT02111837 -
Effects of Specific Lipid Fractions-enriched Infant Formulae
|
N/A | |
Recruiting |
NCT05119166 -
International Milk Composition (IMiC) Consortium
|
||
Completed |
NCT02142647 -
Effect of Protein From Complementary Foods on Infant Growth, Body Composition and Gut Health
|
N/A | |
Completed |
NCT00388141 -
Nursing and Nurturing Premature Infants
|
Phase 0 | |
Completed |
NCT01084109 -
First Bites: Complementary Feeding - A Global Network Cluster Randomized Controlled Trial
|
Phase 3 | |
Completed |
NCT02307760 -
Evaluation of Human Milk Fortifiers in Preterm Infants
|
N/A | |
Recruiting |
NCT03808207 -
Human Milk Lipid Profile Assessment and Influences of Mother's Diet
|
N/A | |
Completed |
NCT03993860 -
Introduction of Fish Early in the Complementary Feeding Period to Improve Infant Growth
|
N/A | |
Terminated |
NCT05804214 -
Observational Study of Infants Fed With Dairy and Plant Based Infant Formula
|